Search for
Ear tissue - Large Biopsy 3-6 cm
Biopsy
Report in 288Hrs
At Home
No Fasting Required
Details
Biopsy of ear lesion.
₹666₹951
30% OFF
Ear Tissue - Large Biopsy 3-6 cm
- Why is it done?
- To obtain tissue samples from ear lesions, growths, or abnormalities for histopathological examination and definitive diagnosis
- To diagnose malignant or benign skin cancers including melanoma, basal cell carcinoma, and squamous cell carcinoma
- To evaluate chronic ear infections, inflammatory conditions, or dermatological disorders affecting the ear
- To assess unusual growths, cysts, or masses in or on the ear canal or auricle
- To determine the extent and grade of malignancy when cancer is suspected
- Typically performed when lesions are 3-6 cm in size, requiring larger tissue samples for complete evaluation
- Normal Range
- Normal Result: No malignant cells present; benign tissue characteristics; normal skin architecture; absence of dysplasia or carcinoma
- Abnormal Result: Presence of malignant cells, dysplasia, carcinoma, or other pathological findings
- Result Categories: Benign, Low-grade dysplasia, High-grade dysplasia/Carcinoma in situ, Invasive carcinoma, or Melanoma (with subtype classification)
- Units of Measurement: Qualitative histopathological findings reported descriptively with tissue specimen size (3-6 cm)
- Interpretation Guide: Normal indicates benign pathology requiring only routine follow-up; abnormal findings determine treatment urgency and type
- Interpretation
- Benign Findings: Include cysts, lipomas, fibromas, seborrheic keratosis, or inflammatory conditions; typically require clinical follow-up only
- Dysplasia (Low-grade): Indicates early cellular changes with low malignancy potential; may require repeat biopsies or close surveillance
- Dysplasia (High-grade)/CIS: Indicates significant cellular abnormalities with increased cancer risk; typically requires surgical excision
- Invasive Carcinoma: Confirms cancer diagnosis; staging and grading (Breslow depth, Clark level, mitotic rate) determine prognosis and treatment approach
- Melanoma: Classified by type (superficial spreading, nodular, lentigo maligna, acral); thickness and ulceration are critical prognostic factors
- Basal Cell Carcinoma (BCC): Lowest malignancy potential; nodular, superficial, or infiltrative subtypes identified; complete excision usually curative
- Squamous Cell Carcinoma (SCC): Higher malignancy potential than BCC; grading (well, moderately, poorly differentiated) and depth influence prognosis
- Factors Affecting Interpretation: Specimen orientation, adequate fixation, presence of margins, previous treatments, immunohistochemical staining results, and molecular studies when applicable
- Clinical Significance: Results guide treatment selection, predict patient outcomes, and determine follow-up imaging/surveillance protocols
- Associated Organs
- Primary Organ System: Integumentary system (skin); external ear structures including auricle, ear canal, and surrounding soft tissues
- Diseases Diagnosed: Skin cancer (melanoma, BCC, SCC), precancerous lesions, dermatitis, psoriasis, lichen planus, lupus erythematosus, fungal infections, and infectious conditions
- Related Conditions: Solar elastosis, actinic damage, chronic sun exposure effects, immunosuppression-related skin cancers, and hereditary cancer syndromes
- Potential Complications: Cancer metastasis to regional lymph nodes, head/neck tissues, or distant organs; nerve involvement; cosmetic disfigurement; infection; and recurrent disease
- Biopsy Site-Specific Risks: Facial nerve involvement, hearing impairment if deep ear canal affected, perforation of tympanum, infection risk, and scarring of auricular cartilage
- Follow-up Tests
- For Malignant Findings: CT/MRI imaging of head and neck; sentinel lymph node biopsy; staging imaging (chest X-ray, CT chest/abdomen); genetic testing (BRCA1/2, CDKN2A for melanoma)
- For Dysplasia Findings: Repeat biopsy in 3-6 months; dermoscopy; immunohistochemistry panel; close clinical surveillance with photographic documentation
- For Benign Findings: Annual clinical skin examination; routine follow-up unless symptomatic; patient self-monitoring for changes
- Complementary Tests: Confocal laser scanning microscopy; ultrasound of suspicious lymph nodes; PET-CT for staging high-grade cancers; flow cytometry for lymphomas
- Molecular/Immunological Studies: BRAF mutation analysis; KIT mutation testing; microsatellite instability; tumor mutational burden; PDL1 expression for immunotherapy planning
- Surveillance Intervals: Melanoma Stage I-II: every 3-6 months for 2 years, then every 6-12 months; High-risk SCC: every 1-3 months; BCC: annual exams unless multiple lesions present
- Fasting Required?
- Fasting Status: No - Fasting is NOT required for this biopsy procedure
- Pre-Procedure Preparation: Routine hygiene; wash affected ear area with soap and water; do not apply topical medications, makeup, or jewelry to biopsy site 24 hours prior
- Medications to Avoid: Aspirin or NSAIDs for 3-7 days before procedure (increases bleeding risk); anticoagulants like warfarin or apixaban (notify provider); discontinue 5-7 days prior if medically appropriate
- Anesthesia Requirements: Local anesthesia used (lidocaine with epinephrine); no systemic anesthesia needed; procedure can be performed in office or outpatient setting
- Patient Instructions: Wear comfortable, loose-fitting clothing; arrange transportation if sedation used; inform provider of allergies (lidocaine, epinephrine); report active infections or fever
- Post-Procedure Care: Keep wound clean and dry; follow dressing change instructions; take prescribed antibiotics if provided; avoid excessive ear manipulation; report signs of infection (increased pain, redness, drainage)
- Activity Restrictions: Avoid water exposure to biopsy site for 7-10 days; no swimming or strenuous exercise for 3-5 days; refrain from headphone/hearing aid use if applicable during healing
How our test process works!
